Trade Summary

4 days ago, Blum Robert I, serving as Pres, CEO at Cytokinetics Inc (CYTK), sold 7,500 shares at $66.63 per share, for a total transaction value of $499,725.00. Following this transaction, Blum Robert I now holds 426,996 shares of CYTK.

This sale represents a 2.00% decrease in Blum Robert I's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 1, 2026, meaning the disclosure happened on the same day as the trade.

Cytokinetics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.